NovaScan Appoints Bob Cook as Chief Operating Officer to Accelerate Commercialization of MarginScan™ Platform

Former Castle Biosciences SVP brings proven diagnostic commercialization and reimbursement leadership to NovaScan’s oncology platform

April 15, 2026 — NovaScan, Inc., a clinical-stage oncology technology company developing point-of-care cancer detection platforms combining spectral bioimpedance with artificial intelligence, today announced the appointment of Robert W Cook, PhD as Chief Operating Officer. In this role, Cook will oversee operational execution, commercialization strategy, and market access initiatives as NovaScan prepares for the clinical and commercial launch of its MarginScan™ platform. For the complete press release, see: https://novascaninc.com/press/dr-robert-cook-coo-2026

Disclaimer: By clicking the link above, you will be entering a third-party website that is not owned or controlled by us. We are not responsible for the content, accuracy, security, privacy practices, or availability of external sites. Any products, services, or information provided on the external website are the responsibility of that site.